.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Merck
Mallinckrodt
Fuji
Cipla
QuintilesIMS
Argus Health
US Army
AstraZeneca
Daiichi Sankyo

Generated: December 18, 2017

DrugPatentWatch Database Preview

OMNIPAQUE 300 Drug Profile

« Back to Dashboard

When do Omnipaque 300 patents expire, and what generic alternatives are available?

Omnipaque 300 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in OMNIPAQUE 300 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.
Drug patent expirations by year for OMNIPAQUE 300

Pharmacology for OMNIPAQUE 300

Medical Subject Heading (MeSH) Categories for OMNIPAQUE 300

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge HealthcareOMNIPAQUE 300iohexolSOLUTION;INJECTION, ORAL, RECTAL018956-003Dec 26, 1985RXYesYes► Subscribe► Subscribe► Subscribe
Ge HealthcareOMNIPAQUE 300iohexolSOLUTION;INJECTION, ORAL, RECTAL020608-002Oct 24, 1995RXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OMNIPAQUE 300

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge HealthcareOMNIPAQUE 300iohexolSOLUTION;INJECTION, ORAL, RECTAL018956-003Dec 26, 1985► Subscribe► Subscribe
Ge HealthcareOMNIPAQUE 300iohexolSOLUTION;INJECTION, ORAL, RECTAL018956-003Dec 26, 1985► Subscribe► Subscribe
Ge HealthcareOMNIPAQUE 300iohexolSOLUTION;INJECTION, ORAL, RECTAL018956-003Dec 26, 1985► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Accenture
Johnson and Johnson
QuintilesIMS
McKesson
Argus Health
Cipla
Queensland Health
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot